File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer
  • Basic View
  • Metadata View
  • XML View
TitleSerum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer
 
AuthorsXia, HHX2 3
Yang, Y2 1
Chu, KM2
Gu, Q2
Zhang, YY4
He, H2
Wong, WM2
Leung, SY2
Yuen, ST2
Yuen, MF2
Chan, AOO2
Wong, BCY2
 
KeywordsCarcinoembryonic antigen
Diagnosis
Gastric cancer
Macrophage migration-inhibitory factor
Prognosis
 
Issue Date2009
 
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
 
CitationCancer, 2009, v. 115 n. 23, p. 5441-5449 [How to Cite?]
DOI: http://dx.doi.org/10.1002/cncr.24609
 
AbstractBACKGROUND: This study aimed to determine the potential diagnostic value of migration-inhibitory factor (MIF) for gastric cancer in patients presenting with dyspepsia and its prognostic value for gastric cancer. METHODS: A cohort of 97 patients with histologically confirmed gastric adenocarcinoma and 222 patients with dyspepsia were recruited. Enzyme-linked immunosorbent assay was used to measure serum MIF and carcinoembryonic antigen (CEA). RESULTS: The serum MIF concentrations were 6554.0 ± 204.1 pg/mL and 1453.7 ± 79.9 pg/mL, respectively, in gastric cancer patients and dyspeptic patients (P < .001). Serum MIF levels increased with the advancing gastric pathologies (P < .001). With the cutoff value of 3230 pg/mL, serum MIF had sensitivity, specificity, and accuracy of 83.5%, 92.3%, and 89.7%, respectively, in diagnosing gastric cancer, whereas the rates were 60.8%, 83.3%, and 76.5%, respectively, for serum CEA. Gastric cancer patients with serum MIF levels above 6600 pg/mL had a lower 5-year survival rate than those with serum MIF level below that level (P = .012). Higher serum CEA levels were also associated with poor survival. The prediction for 5-year survival was even better (P = .0001), using a combination of serum MIF and CEA. CONCLUSIONS: Serum MIF level, which correlates with gastric MIF expression, is a better molecular marker than CEA in diagnosing gastric cancer in patients presenting with dyspepsia. A combination of serum MIF and CEA predicts 5-year survival better than the individual test. © 2009 American Cancer Society.
 
ISSN0008-543X
2012 Impact Factor: 5.201
2012 SCImago Journal Rankings: 2.407
 
DOIhttp://dx.doi.org/10.1002/cncr.24609
 
ISI Accession Number IDWOS:000271918600013
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorXia, HHX
 
dc.contributor.authorYang, Y
 
dc.contributor.authorChu, KM
 
dc.contributor.authorGu, Q
 
dc.contributor.authorZhang, YY
 
dc.contributor.authorHe, H
 
dc.contributor.authorWong, WM
 
dc.contributor.authorLeung, SY
 
dc.contributor.authorYuen, ST
 
dc.contributor.authorYuen, MF
 
dc.contributor.authorChan, AOO
 
dc.contributor.authorWong, BCY
 
dc.date.accessioned2010-09-06T07:19:35Z
 
dc.date.available2010-09-06T07:19:35Z
 
dc.date.issued2009
 
dc.description.abstractBACKGROUND: This study aimed to determine the potential diagnostic value of migration-inhibitory factor (MIF) for gastric cancer in patients presenting with dyspepsia and its prognostic value for gastric cancer. METHODS: A cohort of 97 patients with histologically confirmed gastric adenocarcinoma and 222 patients with dyspepsia were recruited. Enzyme-linked immunosorbent assay was used to measure serum MIF and carcinoembryonic antigen (CEA). RESULTS: The serum MIF concentrations were 6554.0 ± 204.1 pg/mL and 1453.7 ± 79.9 pg/mL, respectively, in gastric cancer patients and dyspeptic patients (P < .001). Serum MIF levels increased with the advancing gastric pathologies (P < .001). With the cutoff value of 3230 pg/mL, serum MIF had sensitivity, specificity, and accuracy of 83.5%, 92.3%, and 89.7%, respectively, in diagnosing gastric cancer, whereas the rates were 60.8%, 83.3%, and 76.5%, respectively, for serum CEA. Gastric cancer patients with serum MIF levels above 6600 pg/mL had a lower 5-year survival rate than those with serum MIF level below that level (P = .012). Higher serum CEA levels were also associated with poor survival. The prediction for 5-year survival was even better (P = .0001), using a combination of serum MIF and CEA. CONCLUSIONS: Serum MIF level, which correlates with gastric MIF expression, is a better molecular marker than CEA in diagnosing gastric cancer in patients presenting with dyspepsia. A combination of serum MIF and CEA predicts 5-year survival better than the individual test. © 2009 American Cancer Society.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationCancer, 2009, v. 115 n. 23, p. 5441-5449 [How to Cite?]
DOI: http://dx.doi.org/10.1002/cncr.24609
 
dc.identifier.doihttp://dx.doi.org/10.1002/cncr.24609
 
dc.identifier.epage5449
 
dc.identifier.hkuros168260
 
dc.identifier.isiWOS:000271918600013
 
dc.identifier.issn0008-543X
2012 Impact Factor: 5.201
2012 SCImago Journal Rankings: 2.407
 
dc.identifier.issue23
 
dc.identifier.openurl
 
dc.identifier.pmid19685530
 
dc.identifier.scopuseid_2-s2.0-72249100819
 
dc.identifier.spage5441
 
dc.identifier.urihttp://hdl.handle.net/10722/76283
 
dc.identifier.volume115
 
dc.languageeng
 
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741
 
dc.publisher.placeUnited States
 
dc.relation.ispartofCancer
 
dc.relation.referencesReferences in Scopus
 
dc.rightsCancer. Copyright © John Wiley & Sons, Inc.
 
dc.subject.meshAged
 
dc.subject.meshDyspepsia - pathology
 
dc.subject.meshFemale
 
dc.subject.meshHumans
 
dc.subject.meshMacrophage Migration-Inhibitory Factors - blood
 
dc.subject.meshMale
 
dc.subject.meshMiddle Aged
 
dc.subject.meshPrognosis
 
dc.subject.meshStomach Neoplasms - blood - diagnosis - mortality
 
dc.subject.meshTumor Markers, Biological - blood
 
dc.subjectCarcinoembryonic antigen
 
dc.subjectDiagnosis
 
dc.subjectGastric cancer
 
dc.subjectMacrophage migration-inhibitory factor
 
dc.subjectPrognosis
 
dc.titleSerum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Xia, HHX</contributor.author>
<contributor.author>Yang, Y</contributor.author>
<contributor.author>Chu, KM</contributor.author>
<contributor.author>Gu, Q</contributor.author>
<contributor.author>Zhang, YY</contributor.author>
<contributor.author>He, H</contributor.author>
<contributor.author>Wong, WM</contributor.author>
<contributor.author>Leung, SY</contributor.author>
<contributor.author>Yuen, ST</contributor.author>
<contributor.author>Yuen, MF</contributor.author>
<contributor.author>Chan, AOO</contributor.author>
<contributor.author>Wong, BCY</contributor.author>
<date.accessioned>2010-09-06T07:19:35Z</date.accessioned>
<date.available>2010-09-06T07:19:35Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>Cancer, 2009, v. 115 n. 23, p. 5441-5449</identifier.citation>
<identifier.issn>0008-543X</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/76283</identifier.uri>
<description.abstract>BACKGROUND: This study aimed to determine the potential diagnostic value of migration-inhibitory factor (MIF) for gastric cancer in patients presenting with dyspepsia and its prognostic value for gastric cancer. METHODS: A cohort of 97 patients with histologically confirmed gastric adenocarcinoma and 222 patients with dyspepsia were recruited. Enzyme-linked immunosorbent assay was used to measure serum MIF and carcinoembryonic antigen (CEA). RESULTS: The serum MIF concentrations were 6554.0 &#177; 204.1 pg/mL and 1453.7 &#177; 79.9 pg/mL, respectively, in gastric cancer patients and dyspeptic patients (P &lt; .001). Serum MIF levels increased with the advancing gastric pathologies (P &lt; .001). With the cutoff value of 3230 pg/mL, serum MIF had sensitivity, specificity, and accuracy of 83.5%, 92.3%, and 89.7%, respectively, in diagnosing gastric cancer, whereas the rates were 60.8%, 83.3%, and 76.5%, respectively, for serum CEA. Gastric cancer patients with serum MIF levels above 6600 pg/mL had a lower 5-year survival rate than those with serum MIF level below that level (P = .012). Higher serum CEA levels were also associated with poor survival. The prediction for 5-year survival was even better (P = .0001), using a combination of serum MIF and CEA. CONCLUSIONS: Serum MIF level, which correlates with gastric MIF expression, is a better molecular marker than CEA in diagnosing gastric cancer in patients presenting with dyspepsia. A combination of serum MIF and CEA predicts 5-year survival better than the individual test. &#169; 2009 American Cancer Society.</description.abstract>
<language>eng</language>
<publisher>John Wiley &amp; Sons, Inc. The Journal&apos;s web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/28741</publisher>
<relation.ispartof>Cancer</relation.ispartof>
<rights>Cancer. Copyright &#169; John Wiley &amp; Sons, Inc.</rights>
<subject>Carcinoembryonic antigen</subject>
<subject>Diagnosis</subject>
<subject>Gastric cancer</subject>
<subject>Macrophage migration-inhibitory factor</subject>
<subject>Prognosis</subject>
<subject.mesh>Aged</subject.mesh>
<subject.mesh>Dyspepsia - pathology</subject.mesh>
<subject.mesh>Female</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Macrophage Migration-Inhibitory Factors - blood</subject.mesh>
<subject.mesh>Male</subject.mesh>
<subject.mesh>Middle Aged</subject.mesh>
<subject.mesh>Prognosis</subject.mesh>
<subject.mesh>Stomach Neoplasms - blood - diagnosis - mortality</subject.mesh>
<subject.mesh>Tumor Markers, Biological - blood</subject.mesh>
<title>Serum macrophage migration-inhibitory factor as a diagnostic and prognostic biomarker for gastric cancer</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0008-543X&amp;volume=115&amp;spage=5441&amp;epage=5449&amp;date=2009&amp;atitle=Serum+macrophage+migration-inhibitory+factor+as+a+diagnostic+and+prognostic+biomarker+for+gastric+cancer</identifier.openurl>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1002/cncr.24609</identifier.doi>
<identifier.pmid>19685530</identifier.pmid>
<identifier.scopus>eid_2-s2.0-72249100819</identifier.scopus>
<identifier.hkuros>168260</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-72249100819&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>115</identifier.volume>
<identifier.issue>23</identifier.issue>
<identifier.spage>5441</identifier.spage>
<identifier.epage>5449</identifier.epage>
<identifier.isi>WOS:000271918600013</identifier.isi>
<publisher.place>United States</publisher.place>
</item>
Author Affiliations
  1. Johns Hopkins University
  2. The University of Hong Kong
  3. Novartis Pharma
  4. Fudan University